Phase II and III trials, performed by the Groupe d’Etude des Lymphomes de I’Adulte (GELA) consortium and the European MCL Network, deployed first-line combination R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone) and R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin) followed by ASCT, demonstrating impressive ORRs and OS with unequivocal superiority to R-CHOP alone3,5. Here, DDIT3 is linked to mantle cell lymphoma.